STOCK TITAN
  1. Home
  2. News
  3. BNGO

Bionano Genomics Inc - BNGO STOCK NEWS

Welcome to our dedicated news page for Bionano Genomics (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bionano Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bionano Genomics's position in the market.

News
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) partners with Diagens to commercialize the first-ever cytogenetic analysis combining OGM and AI. Diagens becomes an OEM partner of Bionano in China, with NMPA approval for OGM reagents. The partnership aims to detect pathogenic structural variants impacting reproductive health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a study using optical genome mapping (OGM) and whole genome sequencing (WGS) to identify genetic variations in pediatric B-cell acute lymphoblastic leukemia. OGM and WGS together can reveal new therapeutic targets and improve personalized medicine by detecting structural variations. OGM uniquely detected 1,255 SVs, while WGS found 66 gene fusions, with OGM identifying an additional 56 fusions missed by WGS. The study suggests OGM's potential in SV detection for better clinical diagnostics in blood cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
News
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) has announced a registered direct offering of 8,733,626 shares of common stock and warrants at an offering price of $1.145 per share. The warrants have an exercise price of $1.02 per share and expire in five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
offering
News
Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a peer-reviewed study showcasing Optical Genome Mapping's (OGM) effectiveness in analyzing solid tumor cancer samples. OGM demonstrated high concordance with traditional cytogenetic techniques, detecting alterations in oncogenes and tumor suppressor genes not found by other methods. Key findings include OGM's ability to detect small aberrations with high resolution, such as loss of CDKN2A/B and chromothripsis in sarcomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
News
Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys™ System at the American Association for Cancer Research Annual Meeting
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announces participation in AACR Annual Meeting 2024, showcasing optical genome mapping (OGM) applications in cancer research. The company introduces new Stratys™ system and previews VIA™ 7.1 software with enhanced capabilities for cancer research. Nine scientific posters will demonstrate OGM's utility in solid tumors, hematological malignancies, cell and gene therapy, and bioprocessing quality control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
none
-
News
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced a study on optical genome mapping in hereditary breast and ovarian cancer, revealing correlations between structural variations, mutated genes, and poor prognosis. OGM detected chromothripsis events and novel gene fusions accurately, potentially aiding in therapy decisions. The study sheds light on the impact of SV heterogeneity in HBOC-related cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
News
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) will participate in the ACMG Annual Clinical Genetics Meeting 2024, showcasing the Stratys™ system for optical genome mapping and presenting findings from early access customers. The event will feature presentations from renowned medical professionals and scientific workshops on OGM's utility in various research areas. Eleven scientific posters will be presented, covering applications in cancer, genetic disorders, and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
-
News
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
Rhea-AI Summary
Bionano Genomics, Inc. reported a strong financial performance for Q4 2023 and FY 2023, with revenue growth of 30% over the previous year, reaching $10.7 million and $36.1 million, respectively. The company achieved significant milestones in OGM system installations and flowcell sales, indicating a 36% increase in installed systems and a 72% increase in flowcells sold compared to the previous year. Key product launches such as the Stratys system and VIA software have been well-received, driving revenue growth. Bionano also saw positive clinical validation results for OGM in prenatal and postnatal studies. The company aims to continue its success in 2024 by focusing on core OGM products, anticipating revenue in the range of $37.0 to $41.0 million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
earnings
-
News
Bionano to Present at TD Cowen’s 44th Annual Health Care Conference
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) announced that Erik Holmlin, CEO, will present at TD Cowen's Health Care Conference on March 6, 2024. The webcast will be available on their website for 30 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
News
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
Rhea-AI Summary
Bionano Genomics, Inc. (BNGO) will host a conference call to report financial results for Q4 and year end 2023, highlighting recent corporate progress. The call will take place on March 5, 2024, at 4:30 p.m. ET. Participants can access the live webcast on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
Stock BNGO logo
Bionano Genomics Inc

Nasdaq:BNGO

BNGO Rankings

#4727 Ranked by Market Cap
#5501 Ranked by Stock Gains
N/A Ranked by Dividends

BNGO Stock Data

52.38M
54.49M
0.5%
11.91%
9.64%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
San Diego

About BNGO

at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o